Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Eli Lilly just scored a major win with its Phase 3 BRAVE-AA-PEDS study. The trial confirmed baricitinib's effectiveness in ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

The researchers tested their new itaconate-based prodrugs in mice and found that at least two of them were highly effective. The treatment was well-absorbed, reduced inflammation, and stimulated hair ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and Louis Garza at Johns Hopkins University, has developed a compound that could ...

Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.